United States President Donald Trump’s planned tariffs on pharmaceuticals have disrupted the industry. Here’s a timeline of ...

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year ...

Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...

Frontline Ventures leads seed round to accelerate Cellbyte’s international expansion, triple its headcount and automate more drug launch workflows Y Combinator-backed startup has scaled to six figures ...

In the past, biosimilar makers have been able to invalidate some of those patents through a sped-up process called “inter ...

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based ...

Health Affairs' Jeff Byers welcomes Stacie Dusetzina of Vanderbilt University Medical Center and David Simon of the University of Connecticut back to the pod to the current state of drug prices, how ...

A new analysis finds medicines often are not accessible countries where they were tested before approval by the FDA, raising ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies have signed deals with it to develop drugs using its AI-based strategy. The ...

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...